ILOPROST in Septic Shock With Persistent Microperfusion Defects (I-MICRO)
Key facts
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 240 people enrolled
- Started
- 3 Jul 2019
- Ended
- 18 Jan 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- ILOPROST
- NaCl
- Record updated
- 3 July 2024
Who can take part
- Age
- 18 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Patients over 18 years of age
- Signed informed consent or inclusion under the emergency provisions of the law (Article L1122 -1-3 of the PHC / modified by Order n°2016-800 of June 16 2016 - art. 2)
- Patients with septic shock defined by the third international definition:; suspected or proven infection,; and organ dysfunction defined by an acute change in total SOFA score >or=2; and persistent hypotension requiring vasopressor treatment to maintain mean arterial pressure > 65 mmHg despite standard of care hemodynamic optimization; and serum lactate level > 2 mmol/L despite standard of care hemodynamic optimization; and persistence of peripheral hypoperfusion (skin mottling and/or finger skin recoloration time > 3sec, and/or knee skin recoloration time > 4sec) despite standard of care hemodynamic optimization; Within 6 to 24 hours after norepinephrine onset
Who cannot take part
- Hypersensitivity to Ilomedin or to any of the excipients
- unstable angina
- severe cardiac rhythm disorders since Norepinephrine onset
- myocardial infarction in the last 6 months
- Conditions where the hemorrhagic risk may be increased due to the effects of Ilomedin on platelets (i.e., evolving hemorrhage, trauma, intracranial hemorrhage, active gastric ulcer)
- Platelet count < 10000 /mm3
- Refusal to participate in the study
- Pregnancy, breastfeeding
- severe hypoxemia (PaO2/FiO2 <100)
- lack of Social Insurance
- persons deprived of liberty
- persons of a protective measure
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Septic shock remains a major cause of death in critically ill patients. Alterations in microcirculation have long been proposed as a key pathophysiological factor of organ dysfunction and death in septic shock patients. Persistence of mottling, prolonged skin recoloration time and cyanosis of the extremities are the easily and frequently observed manifestations of these microcirculatory disorders. Ilomedin is a prostaglandin analog with a potent vasodilatory effect together with anti-thrombotic properties (inhibition of platelet aggregation) preferentially at the microcirculatory level. An increase in cardiac output with increased arterial oxygen delivery has been observed in clinical and preclinical studies with no episodes of hypotension. Improvement in mesenteric perfusion has moreover been observed in experimental sepsis using Ilomedin. Our group has furthermore reported that administration of Ilomedin in patients with refractory septic shock (peripheral hypoperfusion) resulted in a rapid and sustained improvement in peripheral perfusion. Altogether, Ilomedin may prevent or improve recovery of organ dysfunction in septic shock patients through recruitment of the microcirculation and, thereby, ultimately improve outcome.
The 2 groups in the trial
- intravenous ILOPROSTTreatment being tested
a first dose of ILOPROST of 0.5ng/kg/ min with increments every 30 minutes up to a maximum of 1,5 ng/kg/min for 48h
Treatment: ILOPROST
- Intravenous PlaceboPlacebo, for comparison
Treatment with intravenous NaCl 0.9% therapy with incremental infusion rate every 30 minutes for 48h
Treatment: NaCl
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- " ILOPROST for Treatment of Septic Shock With Persistent Microperfusion Defects ", a Double-blind, Randomized Controlled Trial:The I-MICRO Trial
- Publications
- Iloprost for the Treatment of Severe Septic Shock with Persistent Hypoperfusion: A Double-Blind, Randomized Controlled Trial.American journal of respiratory and critical care medicine, 2025
- The I-MICRO trial, Ilomedin for treatment of septic shock with persistent microperfusion defects: a double-blind, randomized controlled trial-study protocol for a randomized controlled trial.Trials, 2020
- Record updated
- 3 July 2024